Trump’s first choice for HHS Secretary, Tom Price, resigned amid reports of inappropriate travel expenses.
Alex Azar, a former HHS official and pharmaceutical executive, will go before the Senate Finance Committee 10 a.m. Jan. 9.
Senate Finance Committee Chairman Orrin Hatch said in a statement reported in The Hill:
Mr. Azar has demonstrated that he has what it takes to lead the Department of Health and Human Services and that he will tackle the challenges facing the American healthcare system head-on.
Scientific American reports when nominating Alex Azar, Trump called him a “star for better healthcare and lower drug prices.” The catch is that Azar, who served as president of pharmaceutical giant Lilly USA until January, has been widely criticized for raising medication costs. During his decade at Lilly, the company tripled the price of its insulin and was fined for colluding to keep its prices high in Mexico.
Read the pros and cons committee members will have to consider in The Scientific American